BR0209652A - Derivados de dipeptìdeos possuindo um grupo 2-tioacila n-terminal, como inibidores de vasopeptidase - Google Patents

Derivados de dipeptìdeos possuindo um grupo 2-tioacila n-terminal, como inibidores de vasopeptidase

Info

Publication number
BR0209652A
BR0209652A BR0209652-8A BR0209652A BR0209652A BR 0209652 A BR0209652 A BR 0209652A BR 0209652 A BR0209652 A BR 0209652A BR 0209652 A BR0209652 A BR 0209652A
Authority
BR
Brazil
Prior art keywords
terminal
dipeptide derivatives
thioacyl group
vasopeptidase inhibitors
inhibitors
Prior art date
Application number
BR0209652-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Anne Cynthia Fink
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0209652A publication Critical patent/BR0209652A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BR0209652-8A 2001-05-15 2002-05-14 Derivados de dipeptìdeos possuindo um grupo 2-tioacila n-terminal, como inibidores de vasopeptidase BR0209652A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29108801P 2001-05-15 2001-05-15
US33957501P 2001-12-11 2001-12-11
PCT/EP2002/005293 WO2002092622A2 (en) 2001-05-15 2002-05-14 Dipeptide derivatives having a n-terminal 2-thioacyl group as vasopeptidase inhibitors

Publications (1)

Publication Number Publication Date
BR0209652A true BR0209652A (pt) 2004-07-13

Family

ID=26966569

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0209652-8A BR0209652A (pt) 2001-05-15 2002-05-14 Derivados de dipeptìdeos possuindo um grupo 2-tioacila n-terminal, como inibidores de vasopeptidase

Country Status (23)

Country Link
US (3) US6777443B2 (enExample)
EP (2) EP2239268A1 (enExample)
JP (1) JP4390458B2 (enExample)
KR (1) KR100908152B1 (enExample)
CN (1) CN1649893A (enExample)
AR (1) AR035890A1 (enExample)
AU (1) AU2002314067B2 (enExample)
BR (1) BR0209652A (enExample)
CA (1) CA2449292A1 (enExample)
CO (1) CO5540347A2 (enExample)
CZ (1) CZ20033077A3 (enExample)
HU (1) HUP0304084A3 (enExample)
IL (1) IL158772A0 (enExample)
MX (1) MXPA03010403A (enExample)
MY (1) MY127495A (enExample)
NO (1) NO20035084L (enExample)
NZ (1) NZ529438A (enExample)
PE (1) PE20030042A1 (enExample)
PL (1) PL366786A1 (enExample)
RU (1) RU2298559C2 (enExample)
SK (1) SK14032003A3 (enExample)
TW (1) TWI295996B (enExample)
WO (1) WO2002092622A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777443B2 (en) * 2001-05-15 2004-08-17 Novartis Ag Dipeptide derivatives
HUP0401014A2 (hu) * 2001-07-06 2004-08-30 Teva Pharmaceutical Industries Ltd. Eljárás 7-amino-szin-3,5-dihidroxi-heptánsavszármazékok előállítására, 6-ciano-szin-3,5-dihidroxi-hexánsav származékokon keresztül
JP4263095B2 (ja) * 2001-09-21 2009-05-13 ノバルティス アクチエンゲゼルシャフト Aceおよびnepの両阻害剤としてのピラン誘導体
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
DE60315795T2 (de) * 2002-01-17 2008-06-05 Novartis Ag Pharmazeutische zusammensetzung enthaltend valsartan und nep-inhibitoren
ES2315510T3 (es) * 2002-06-13 2009-04-01 Novartis Ag Sales de calcio de estatinas derivadas del indol.
WO2005118166A2 (en) 2004-06-04 2005-12-15 Teva Pharmaceutical Industries, Ltd. Pharmaceutical composition containing irbesartan
US7816347B2 (en) * 2004-12-15 2010-10-19 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and HMG CoA reductase inhibitors
JP2008533109A (ja) * 2005-03-14 2008-08-21 オリオン コーポレーション 利尿を促進するための複合治療
US7390789B2 (en) * 2005-09-13 2008-06-24 William H Simmons Thio-containing inhibitors of aminopeptidase P, and compositions thereof
US7400236B2 (en) 2005-10-21 2008-07-15 Gm Global Technology Operations, Inc. Vehicular lane monitoring system utilizing front and rear cameras
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
US20120157387A1 (en) * 2006-11-28 2012-06-21 Apotex Technologies Inc. Orally bioavailable d-gamma-glutamyl-d-tryptophan
TW200838501A (en) 2007-02-02 2008-10-01 Theravance Inc Dual-acting antihypertensive agents
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
TWI406850B (zh) * 2007-06-05 2013-09-01 Theravance Inc 雙效苯并咪唑抗高血壓劑
JP2010538071A (ja) * 2007-09-07 2010-12-09 セラヴァンス, インコーポレーテッド 二重作用性降圧剤
EP2225210B1 (en) 2007-12-11 2012-04-25 Theravance, Inc. Dual-acting benzoimidazole derivative and their use as antihypertensive agents
JP2011518884A (ja) 2008-04-29 2011-06-30 セラヴァンス, インコーポレーテッド 二重活性抗高血圧剤
US7863309B2 (en) 2008-07-24 2011-01-04 Theravance, Inc. Dual-acting antihypertensive agents
US7956054B2 (en) 2009-07-07 2011-06-07 Theravance, Inc. Dual-acting pyrazole antihypertensive agents
EP2456762B1 (en) 2009-07-22 2013-10-16 Theravance, Inc. Dual-acting oxazole antihypertensive agents
WO2011090929A1 (en) 2010-01-19 2011-07-28 Theravance, Inc. Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
CA2831429A1 (en) * 2011-03-31 2012-10-04 Apotex Technologies Inc. Prodrugs of d-gamma-glutamyl-d-tryptophan and d-gamma- glutamyl-l-tryptophan
US9212206B1 (en) * 2014-11-24 2015-12-15 William H Simmons 4-Fluoro-Thio-containing inhibitors of APP2, compositions thereof and method of use
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
US11396497B2 (en) 2018-05-04 2022-07-26 New Mexico Tech University Research Park Corporation Proteasome inhibitors
CN113956183B (zh) * 2021-10-28 2023-06-20 成都市科隆化学品有限公司 一种Boc-Ser(Bzl)-OH及其制备方法
WO2024230583A1 (zh) * 2023-05-05 2024-11-14 上海济煜医药科技有限公司 一种短肽类化合物及其制备方法和医药应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3432307A1 (de) * 1984-09-03 1986-04-10 Boehringer Ingelheim KG, 6507 Ingelheim Aminosaeurederivate, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen
ES2074257T3 (es) * 1989-11-27 1995-09-01 Santen Pharmaceutical Co Ltd Derivados de aminoacidos.
FR2679564A1 (fr) * 1991-07-23 1993-01-29 Inst Nat Sante Rech Med Nouveaux acylmercaptoalcanoldipeptides, leur preparation et les compositions qui les contiennent.
EP0580550B1 (en) 1992-07-21 1997-10-22 Novartis AG Oxamic acid derivatives as hypocholesteremic agents
US5432186A (en) * 1993-11-16 1995-07-11 Ciba-Geigy Corporation Cyclic amino acid derivatives
US5508266A (en) * 1994-06-22 1996-04-16 Ciba-Geigy Corporation Gem-disubstituted amino acid derivatives
CA2215211A1 (en) * 1995-03-31 1996-10-03 Takeda Chemical Industries, Ltd. Cysteine protease inhibitor
DE69632821T2 (de) * 1995-04-25 2005-08-25 Daiichi Fine Chemical Co., Ltd., Takaoka In wasser hochlöslicher metalloproteinase-inhibitor
AU710502B2 (en) * 1995-05-10 1999-09-23 Darwin Discovery Limited Peptidyl compounds which inhibit metalloproteinase and TNF liberation and their therapeutic use
CA2223088A1 (en) * 1995-06-07 1996-12-19 Bob Dale Brown Novel carbamate-based cationic lipids
US6245809B1 (en) * 1996-12-09 2001-06-12 Cor Therapeutics Inc. Integrin antagonists
US6492421B1 (en) * 1997-07-31 2002-12-10 Athena Neurosciences, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
DE19745151A1 (de) 1997-10-14 1999-04-15 Basf Ag Neue Verbindungen zur Behandlung von Krankheiten, die mit der biologischen Wirkung von Endothelin assoziiert sind
FR2770844A1 (fr) 1997-11-10 1999-05-14 Inst Nat Sante Rech Med Inhibiteurs de toxines clostridiales et compositions pharmaceutiques les contenant
AU1457299A (en) * 1997-11-12 1999-05-31 Ariad Pharmaceuticals, Inc. Novel signal transduction inhibitors, compositions containing them
EP1073674A1 (en) 1998-04-23 2001-02-07 Novartis AG Thiol inhibitors of endothelin-converting enzyme
ATE288922T1 (de) 1998-04-23 2005-02-15 Novartis Pharma Gmbh Bestimmte heteroaryl substituierte thiol inhibitoren von endothelin wechselnden enzymen
EP1140984B1 (en) 1998-12-31 2003-02-12 Aventis Pharmaceuticals Inc. Selective inhibitors of mmp-12
FR2788526B1 (fr) 1999-01-20 2002-07-05 Inst Nat Sante Rech Med Composes tripeptidiques utiles a titre d'hinhibiteurs selectifs de l'aminopeptidase a et compositions pharmaceutiques correspondantes
CO5160290A1 (es) 1999-03-29 2002-05-30 Novartis Ag Derivados de acido fenoxifeniloxamico sustituido .
US6503949B1 (en) * 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
GB9917909D0 (en) * 1999-07-31 1999-09-29 Synphar Lab Inc Cysteine protease inhibitors
US6495522B1 (en) * 1999-08-27 2002-12-17 Cytovia, Inc. Substituted alpha-hydroxy acid caspase inhibitors and the use thereof
US6803383B2 (en) * 2000-03-27 2004-10-12 The Scripps Research Institute Inhibition of angiogenesis and tumor growth
EP1267855A2 (en) 2000-04-03 2003-01-02 Bristol-Myers Squibb Company Vasopeptidase inhibitors to treat isolated systolic hypertension
PE20020082A1 (es) 2000-04-12 2002-02-21 Novartis Ag Composicion farmaceutica que comprende un inhibidor de aldosterona-sintasa y un antagonista del receptor de angiotensina ii (at1)
US20020013307A1 (en) 2000-05-23 2002-01-31 Pablo Lapuerta Use of vasopeptidase inhibitors to treat or slow the progression of cognitive dysfunction and to treat and/or prevent dementia
US6777443B2 (en) * 2001-05-15 2004-08-17 Novartis Ag Dipeptide derivatives

Also Published As

Publication number Publication date
AU2002314067B2 (en) 2006-03-16
TWI295996B (en) 2008-04-21
JP4390458B2 (ja) 2009-12-24
PL366786A1 (en) 2005-02-07
EP1392720A2 (en) 2004-03-03
RU2003134153A (ru) 2005-06-10
KR100908152B1 (ko) 2009-07-16
WO2002092622A8 (en) 2004-01-22
SK14032003A3 (sk) 2004-06-08
PE20030042A1 (es) 2003-02-28
EP2239268A1 (en) 2010-10-13
MY127495A (en) 2006-12-29
CN1649893A (zh) 2005-08-03
US20020183260A1 (en) 2002-12-05
MXPA03010403A (es) 2004-03-09
CO5540347A2 (es) 2005-07-29
AR035890A1 (es) 2004-07-21
US6992105B2 (en) 2006-01-31
WO2002092622A2 (en) 2002-11-21
NO20035084D0 (no) 2003-11-14
US6777443B2 (en) 2004-08-17
WO2002092622A3 (en) 2003-04-10
US20040235754A1 (en) 2004-11-25
HUP0304084A3 (en) 2010-10-28
US20060058242A1 (en) 2006-03-16
CZ20033077A3 (cs) 2004-02-18
KR20030096401A (ko) 2003-12-24
IL158772A0 (en) 2004-05-12
NZ529438A (en) 2005-07-29
HUP0304084A2 (hu) 2004-12-28
RU2298559C2 (ru) 2007-05-10
CA2449292A1 (en) 2002-11-21
JP2005504011A (ja) 2005-02-10
NO20035084L (no) 2004-01-15

Similar Documents

Publication Publication Date Title
CO5540347A2 (es) Derivados de dipeptido que contiene un grupo 2-tioacilo n-terminal como inhibidores de vasopeptidasa
BR0309281A (pt) Triaril-oxi-espiro-pirimidino-2,4,6-trionas inibidoras de metaloproteinases
ATE226193T1 (de) Substituierte zyklische amine als metalloproteaseinhibitoren
DE60035037D1 (de) Caspase inhibitoren und ihre verwendung
DE60022508D1 (de) Inhibitoren von serin proteasen
WO2002030944A3 (en) Fluorescent nucleobase conjugates having anionic linkers
BR0109588A (pt) Inibidores de caspase de carbamato e usos destes
ATE253545T1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
ATE326454T1 (de) Neue bernsteinsäure derivative als cysteine- protease-inhibitoren
DE60029799D1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
ATE232873T1 (de) Phosphonsaürederivate als ptp-1b-inhibitoren
DK1273299T3 (da) Minoxidilinindeholdende praparater
PA8521801A1 (es) Derivados de ciclopentil-glutaramida como inhibidores de endopeptidasa neutra
BR0116166A (pt) Inibidores da serina protease
DE69630701D1 (de) Phosphor enthaltende hemmer von cystein- und serin-proteasen
BR0212535A (pt) Compostos e composições como inibidores de catepsina
DE60134230D1 (de) Substraten und nachweise zur wirksamkeit von beta-secretase
BR9909805A (pt) Certos inibidores de tiol de enzima de conversão de endotelina
BR0014990A (pt) Derivados de tetrahidrotiopirano ranftalazinona como inibidores de pde4
EA200700976A1 (ru) Соединения в виде молекул-конъюгатов, обладающих повышенной активностью в отношении включения клеткой
BR0115996A (pt) Sulfamidotienopirimidinas
ATE288922T1 (de) Bestimmte heteroaryl substituierte thiol inhibitoren von endothelin wechselnden enzymen
BRPI0411664A (pt) composição oral antiplaca aquosa estável
TW200407325A (en) Novel interleukin-1β converting enzyme inhibitors
BRPI0410157A (pt) bioisostéreos de actinonina

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUI DADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 10A ANUIDADE.